Tongji Cancer Research Institute, Tongji Hospital, Tongji Medical College in Huazhong University of Science and Technology, Wuhan, Hubei, China.
Eur Rev Med Pharmacol Sci. 2021 Mar;25(5):2409-2414. doi: 10.26355/eurrev_202103_25281.
The COVID-19 (Corona Virus Disease 2019) outbreak, which seriously affected people's lives across the world, has not been effectively controlled. Previous studies have demonstrated that SARS-COV-2 (Severe acute respiratory syndrome coronavirus 2) infecting host cells mainly rely on binding to receptor proteins, namely ACE2 and TMPRSS2. COVID-19 transmission is faster than the severe acute respiratory syndrome (SARS) pneumonia outbreak in 2002. This is mainly attributed to the different pathways of virus-infected host cells, coupled with patients' atypical clinical characteristics. SARS-CoV-2 is mainly transmitted through respiratory droplets and contact, infecting lung tissues before damaging other body organs, such as the liver, brain, kidney and heart. The present study identified potential target genes for SARS-COV-2 receptors, ACE2 and TMPRSS2, in normal human lung tissue. The findings provide novel insights that will guide future drug development approaches for treatment of COVID-19.
新型冠状病毒肺炎（COVID-19）疫情严重影响了全球人民的生活，但目前仍未得到有效控制。先前的研究表明，严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染宿主细胞主要依赖于与受体蛋白，即血管紧张素转换酶 2（ACE2）和跨膜丝氨酸蛋白酶 2（TMPRSS2）的结合。与 2002 年严重急性呼吸综合征（SARS）肺炎疫情相比，COVID-19 的传播速度更快。这主要归因于病毒感染宿主细胞的不同途径，再加上患者非典型的临床特征。SARS-CoV-2 主要通过呼吸道飞沫和接触传播，在损害其他器官，如肝脏、大脑、肾脏和心脏之前，先感染肺部组织。本研究在正常人体肺组织中鉴定出了 SARS-CoV-2 受体 ACE2 和 TMPRSS2 的潜在靶基因。这些发现为未来针对 COVID-19 的治疗方法提供了新的见解。
